CDO1 and neoplasm: [7–16] Additional study has further shown the clinical utility of tumor diagnosis using CDO1 promoter DNA methylation in an endoscopic retrograde cholangiography (ERCP) solution of BTC as alternate cytology test.[17] Nevertheless, there have no reports with regard to clinico-pathological relevance of CDO1 methylation in primary BTC.